The FDA has approved trilaciclib (Cosela) as a first-in-class agent to help reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving chemotherapy for extensive-stage small cell lung cancer.
Targeted Oncology Staff
Articles by Targeted Oncology Staff
The FDA has granted approval to lisocabtagene maraleucel a CD19-targeting chimeric antigen receptor T-cell therapy, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma who have received at least 2 prior lines of systemic therapy.
During a Targeted Oncology Case-Based Peer Perspectives event, Sara M. Tolaney, MD, MPH, discussed therapies available for the treatment of a 42-year-old woman with HER2-positive breast cancer.
Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, reviewed the prognostic tools used to find indicators of response to treatment in patients with myelofibrosis, during a Targeted Oncology Case-Based Peer Perspective Roundtable discussion.
During a Targeted Oncology Case-Based Peer Perspectives event, Guilherme Rabinowits, MD, medical oncologist/hematologist, Miami Cancer Institute, discussed the case of 69-year-old patients with cutaneous squamous cell carcinoma.
The combination of atezolizuma plus carboplatin and etoposide demonstrated improvement in overall survival and progression-free survival when given as maintenance therapy to patients extensive stage small cell lung cancer, according to the latest findings from the IMpower 133 trial.
During a Targeted Oncology Case-Based Peer Perspectives Roundtable, Swaminathan P. Iyer, MD, discussed FDA-approved therapy option for a patient with T-cell lymphoma.
The role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia is supported by clinical trial research. During a Targeted Oncology Case-Based Peer Perspectives Roundtable event, Peter Hillmen, MB ChB, PhD, provided evidence around acalabrutinib for the case of a 61-year-old woman.
During a Targeted Oncology Case-Based Peer Perspective Roundtable, Mary Jo J. Fidler, MD, discussed targeting VEGFR and EGFR in patients with non–small cell lung cancer.
This week, the FDA granted Priority Review designation to 4 therapies. The designations were across multiple malignancies and cancer-related conditions, including for patients with post-transplant complications, gastric/gastroesophageal junction and esophageal adenocarcinoma, as well as with squamous cell carcinoma of the anal canal.
In an interview with Targeted Oncology, Benjamin Solomon, MBBS, PhD, discussed the findings from the CROWN study that compared lorlatinib with crizotinib as treatment of patients with ALK-positive non-small cell lung cancer.
During a Targeted Oncology Case-Based Peer Perspectives Roundtable event, Alex Mejia-Garcia, MD, medical oncologist, Cleveland Clinic, discussed the use of daratumumab as treatment of multiple myeloma. The discussion was based on the case scenario of a 51-year-old patient.
Gilles Salles, MD, PhD, discussed sequencing of CD-19 directed therapies for a 74-year-old patient with diffuse large B-cel lymphoma during a Targeted Oncology Case-Based Peer Perspective Roundtable event.
During a Targeted Oncology Case-Based Peer Perspectives Roundtable event, Ruta D. Rao, MD, discussed the case of 42-year-old woman with HER2-positive breast cancer.
During a Targeted Oncology Case-Based Peer Perspectives Roundtable, two Mayo Clinic experts, Alan H. Bryce, MD, and Roxana S. Dronca, MD, discuss treatment options for a 66-year-old woman with urothelial carcinoma.
For the second-line treatment of patients with chronic lymphocytic leukemia, the armamentarium includes many therapies and strategies. Danielle Brander, MD, assistant professor of Medicine at Duke Cancer Institute, discussed how to select treatment for patients during a Targeted Oncology Case-Based Peer Perspectives event.
During a Targeted Oncology Case-Based Peer Perspectives event, Arash Rezazadeh Kalebasty, MD, discussed genomic testing and evidence-based treatment of a 60-year-old male patient with prostate cancer.
For patients with cutaneous squamous cell carcinoma who refuse surgery as a treatment for their disease, systemic therapies like cemiplimab, nivolumab, avelumab, and pembrolizumab can still improve outcomes, explained Asim Amin, MD, PhD, a medical oncologist, Levine Cancer Institute. Atrium Health during a Targeted Oncology Case-Based Peer Perspectives event.
Osimertinib has been a successful therapy for the treatment of EGFR-positive non–small cell lung cancer, surpassing the effects of chemotherapy. In he adjuvant setting, physicians questions when and how to use osimertinib.
Multiple treatment options exist for patients with unresectable locally advanced lung adenocarcinoma. Zofia Piotrowska, MD, examined the options during a Targeted Oncology Case-Based Peer Perspectives event.
Solly Chedid, MD, led a discussion with a group of peers about the treatment of infiltrative basal cell carcinoma in a 88-year-old patient during a Targeted Oncology Case-Based Peer Perspectives event.
During a Targeted Oncology Case-Based Peer Perspectives event, Catherine Frenette, MD, discussed the case of a 77-year-old patients with hepatocellular carcinoma.
During a Targeted Oncology Case-Based Peer Perspectives event, Haifaa Abdulhaq, MD, director, Hematology, and associate clinical professor of Medicine at UCSF Fresno discussed the case of a 63-year-old patient with lymphoma with concurrent MYC and BCL2 rearrangements.
During a Targeted Oncology Case Based Peer Perspectives event, Bradley Monk, MD, discussed how the use of molecular testing can improve treatment decisions for ovarian cancer.
During a Targeted Oncology Case-Based Peer Perspective event, Rafael Fonseca, MD, discussed the case of a 72-year-old patient with multiple myeloma.
The plan of treatment for a 69-year-old patient with poorly differentiated, infiltrative, cutaneous squamous cell carcinoma was the topic of discussion among Dan Paul Zandberg, MD, and other clinicians in attendance during a Targeted Oncology Case-Based Peer Perspectives event.
During a Targeted Oncology Case-Based Peer Perspective event, Jonathon B. Cohen, MD, MS, discussed therapeutic options for a 71-year-old patients with chronic lymphocytic leukemia and a genomic aberration.
During a Targeted Oncology Case-Based Peer Perspective event, Chaitali S. Nangia, MD, reviewed the case of a 75-year-old patient with infiltrative basal cell carcinoma.
Anthony A. Meluch, MD, medical oncologist, Tennessee Oncology, discussed treatment options for high-risk adenocarcinoma of the prostate based on the case of a 75-year-old patient during a Targeted Oncology Case-Based Peer Perspectives event.
During a Targeted Oncology Case Based Peer Perspective event, Mayer N. Fishman, MD, PhD, discussed the case of a 60-year-old man with progressing prostate cancer.